Immunosuppressive therapy for progressive idiopathic membranous nephropathy: a cost-effectiveness analysis in China

ABSTRACT:

Background

This study aims to evaluate the cost-effectiveness of immunosuppressive therapy for patients with progressive idiopathic membranous nephropathy (IMN) from the Chinese healthcare system perspective.

Methods

To estimate the cost-effectiveness of four regimens namely cyclophosphamide, cyclosporine, rituximab and tacrolimus-rituximab in treatment of IMN recommended by the updated Kidney Disease: Improving Global Outcomes (KDIGO) guideline 2021, a Markov model with five discrete states (active disease, remission, dialysis, kidney transplant and death) based on IMN patients aged 50 or above over a 30-years time horizon was constructed. Total costs were imputed from the Chinese healthcare system perspective, and health outcomes were converted into quality-adjusted lif

SUBMITTER: Xu W 

PROVIDER: S-EPMC10091593 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature